EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study

Hyo-Jeong Ahn iD, So-Ryoung Lee iD, JungMin Choi iD, Kyung-Yeon Lee iD, Soonil Kwon iD, Eue-Keun Choi iD, Seil Oh iD, Gregory Y H Lip iD

Europace · 2024

DOI: 10.1093/europace/euae033 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Europace, 2024. Verfasst von Hyo-Jeong Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Chongno-gu, Seoul 03080, Republic of Korea. Hauptthemen laut MEDLINE: Stroke, Atrial Fibrillation, Brain Ischemia, Ischemic Stroke. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIEHS NIH HHS, the Korean Cardiac Research Foundation, Ministry of Health & Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Data on the optimal use of antithrombotic drugs and associated clinical outcomes in patients with atrial fibrillation (AF) and acute ischaemic stroke (IS) are limited. We investigated the prescription patterns of antithrombotics in community practice and long-term clinical prognosis according to early post-stroke antithrombotic therapy in patients with AF and acute IS. Methods and results Patients with AF who were admitted for acute IS at a single tertiary hospital in 2010–2020 were retrospectively reviewed. Clinical profiles including the aetiology of stroke and prescription patterns of antithrombotics were identified. The net clinical outcome (NCO)—the composite of recurrent stroke, any bleeding, hospitalization or emergency department visits for cardiovascular (CV) events, and death—was compared according to the antithrombotic therapy at the first outpatient clinic visit [oral anticoagulation (OAC) alone vs. antiplatelet (APT) alone vs. OAC/APT(s)] following discharge. A total of 918 patients with AF and acute IS (mean age, 72.6 years; male, 59.3%; mean CHA₂DS₂-VASc score 3.3) were analysed. One-third (33.9%, n = 310) of patients were simultaneously diagnosed with AF and IS. The most common aetiology of IS was cardioembolism (71.2%), followed by undetermined aetiology (19.8%) and large artery atherosclerosis (6.0%). OAC, APT(s), and concomitant OAC and APT(s) were prescribed in 33.4%, 11.1%, and 53.4% of patients during admission that changed to 67.0%, 9.1%, and 21.7% at the first outpatient clinic, and were mostly continued up to one year after IS. Non-prescription of OAC was observed in 11.3% of post-stroke patients with AF. During a median follow-up of 2.1 years, the overall incidence rate of NCO per 100 patient-year (PY) was 20.14. APT(s) monotherapy presented the highest cumulative risk of NCO (adjusted hazard ratio 1.47, 95% confidence interval 1.08–2.00, P = 0.015; with reference to OAC monotherapy) mainly driven by the highest rates of recurrent stroke and any bleeding. OAC/APT(s) combination therapy was associated with a 1.62-fold significantly higher risk of recurrent stroke (P = 0.040) and marginally higher risk of any bleeding than OAC monotherapy.

Conclusion

Approximately one-third of acute IS in AF have a distinctive mechanism from cardioembolism. Although APT was frequently prescribed in post-stroke patients with AF, no additive clinical benefit was observed. Adherence to OAC treatment is essential to prevent further CV adverse events in patients with AF and IS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeAtrial FibrillationBrain IschemiaIschemic StrokeHumansMaleAgedFibrinolytic AgentsAnticoagulantsPlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsHemorrhageCohort StudiesTreatment OutcomeAdministration, Oral

Stichwörter der Autor:innen

AntiplateletAntithromboticsAtrial fibrillationIschaemic strokeOral anticoagulation

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Chongno-gu, Seoul 03080, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Chongno-gu, Seoul 03080, Republic of Korea.
  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Chest & Heart Hospital, Liverpool, UK.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Hyo-Jeong Ahn, So-Ryoung Lee, JungMin Choi, Kyung-Yeon Lee, Soonil Kwon, Eue-Keun Choi, Seil Oh, Gregory Y H Lip

Förderung

  • NIEHS NIH HHS
  • the Korean Cardiac Research Foundation
  • Ministry of Health & Welfare
  • Korea government
  • Ministry of Trade, Industry and Energy
  • Ministry of Food and Drug Safety

Zitieren

APA

Ahn, H. J., Lee, S. R., Choi, J., Lee, K. Y., Kwon, S., Choi, E. K., Oh, S., & Lip, G. Y. H. (2024). Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study. Europace. https://doi.org/10.1093/europace/euae033

Vancouver

Ahn HJ, Lee SR, Choi J, Lee KY, Kwon S, Choi EK, et al. Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study. Europace. 2024. doi:10.1093/europace/euae033

BibTeX
@article{Ahn2024,
  author = {Ahn, Hyo-Jeong and Lee, So-Ryoung and Choi, JungMin and Lee, Kyung-Yeon and Kwon, Soonil and Choi, Eue-Keun and Oh, Seil and Lip, Gregory Y H},
  title = {Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study},
  journal = {Europace},
  year = {2024},
  doi = {10.1093/europace/euae033}
}
Kostenlos starten →